Successful preventive treatment with cyclosporine in a patient with relapsed/refractory immune-mediated thrombotic thrombocytopenic purpura: a case report and review of the literature
暂无分享,去创建一个
I. Hanamura | A. Takami | M. Matsumoto | K. Sakai | Shohei Mizuno | K. Uchino | Saki Shinohara | Akifumi Matsuhisa | Yusuke Iida | Yuta Nakano | Saori Matsumura | Jo Kanasugi | Soichi Takasugi | Ayano Nakamura | Tomohiro Horio | Satsuki Murakami | H. Yamamoto
[1] M. Matsumoto,et al. Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan , 2020, International Journal of Hematology.
[2] S. Vesely,et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura , 2020, Journal of thrombosis and haemostasis : JTH.
[3] B. Lämmle,et al. Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. , 2020, Blood.
[4] M. Murata,et al. HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR. , 2020, Blood.
[5] Shruti Chaturvedi,et al. How targeted therapy disrupts the treatment paradigm for acquired TTP - the risks, benefits and unknowns. , 2019, Blood.
[6] Flora Peyvandi,et al. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura , 2019, The New England journal of medicine.
[7] B. Lämmle,et al. Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab , 2018, Thrombosis and Haemostasis.
[8] J. George,et al. Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura. , 2017, Blood advances.
[9] Y. Miyakawa,et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan , 2017, International Journal of Hematology.
[10] P. Coppo,et al. Thrombotic thrombocytopenic purpura. , 2017, Blood.
[11] Ang Li,et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. , 2017, The Lancet. Haematology.
[12] W. Clark,et al. Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura , 2016, BMJ Case Reports.
[13] Mitsuru Murata,et al. Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy , 2016, International Journal of Hematology.
[14] A. ten Brinke,et al. CD4+ T cells from patients with acquired thrombotic thrombocytopenic purpura recognize CUB2 domain-derived peptides. , 2016, Blood.
[15] B. Chong,et al. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). , 2015, Blood.
[16] M. Çetiner,et al. Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature , 2013, Transfusion.
[17] A. ten Brinke,et al. Preferential HLA-DRB1*11-dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells. , 2012, Blood.
[18] J. Voorberg,et al. The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells. , 2012, Blood.
[19] G. Choukroun,et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center , 2012, Critical care medicine.
[20] Gerald McGwin,et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. , 2012, Arthritis and rheumatism.
[21] J. Voorberg,et al. Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain , 2011, Haematologica.
[22] F. Lansigan,et al. Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13. , 2011, Rheumatology.
[23] S. Hidaka,et al. Successful Treatment with Cyclosporine of Thrombotic Thrombocytopenic Purpura Refractory to Corticosteroids and Plasma Exchange , 2011, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[24] D. Consonni,et al. Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura , 2010, British journal of haematology.
[25] S. Ferrari,et al. IgG subclass distribution of anti‐ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura , 2009, Journal of thrombosis and haemostasis : JTH.
[26] K. Jhaveri,et al. Treatment of refractory thrombotic thrombocytopenic purpura using multimodality therapy including splenectomy and cyclosporine. , 2009, Transfusion and Apheresis Science.
[27] A. Nosari,et al. Cyclosporine therapy in refractory/relapsed patients with thrombotic thrombocytopenic purpura , 2009, American journal of hematology.
[28] J. George,et al. Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura , 2008, American journal of hematology.
[29] J. George,et al. Ciclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long‐term follow‐up with serial analysis of ADAMTS13 activity , 2007, British journal of haematology.
[30] É. Oksenhendler,et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. , 2007, Blood.
[31] J. George,et al. An evaluation of ciclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura , 2007 .
[32] J. George,et al. An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. , 2007, British journal of haematology.
[33] T. Matsuyama,et al. Novel monoclonal antibody‐based enzyme immunoassay for determining plasma levels of ADAMTS13 activity , 2006, Transfusion.
[34] J. George,et al. An evaluation of cyclosporine alone for the treatment of early recurrences of thombotic thrombocytopenic purpura , 2006, Journal of thrombosis and haemostasis : JTH.
[35] K. Remes,et al. Excellent response of refractory life-threatening thrombotic thrombocytopenic purpura to cyclosporine treatment. , 2004, Clinical and laboratory haematology.
[36] B. Borisch,et al. Mechanism of action of rituximab , 2002, Anti-cancer drugs.
[37] Yong,et al. Successful use of cyclosporine A in the treatment of refractory thrombotic thrombocytopenic purpura , 1998, British journal of haematology.
[38] J. Damoiseaux,et al. Multiple effects of cyclosporin A on the thymus in relation to T-cell development and autoimmunity. , 1997, Clinical immunology and immunopathology.
[39] J. Brennan,et al. Refractory thrombotic thrombocytopenic purpura treated with cyclosporine , 1996, American journal of hematology.
[40] N. Maurin,et al. Cyclosporine for Thrombotic Thrombocytopenic Purpura , 1993, Annals of Internal Medicine.
[41] H. Mcdevitt,et al. Autoimmune diseases: the failure of self tolerance. , 1990, Science.